Introduction
N eurological disorders are a significant burden to society worldwide, especially in countries where a growing inflammatory response is beneficial, detrimental, or incidental. Nakajima and Kohsaka [2] proposed that neuroinflammation in acute injuries is beneficial, whereas it will lead to neuronal cell death in chronic diseases. When the exact role of neuroinflammation in different neurological disorders is unraveled, this will inevitably lead to early diagnosis, possible therapeutic intervention, and improved treatment.
One of the key players in neuroinflammation is the microglia cell, which provides the first line of defense against brain tissue injuries. In the healthy central nervous system, microglia cells continuously survey their microenvironment by rapid extension and extraction of their ramified processes [3, 4] . In response to a wide variety of central nervous system insults, microglia cells become activated and change from their ramified state into amoeboid morphology. The activation of microglia cells is accompanied by an increased expression of the translocator protein (TSPO), an 18 kDa component of a heteromeric complex. The expression of the TSPO is low in the healthy brain, but is highly upregulated in neuroinflammation.
Positron emission tomography (PET) is a non-invasive imaging technique that can be used to study the role of neuroinflammation in neurological disorders, using the TSPO as a biomarker. PET has already been used in numerous clinical studies to visualize activated microglia cells using the isoquinoline [ 11 C]-(R)-PK11195 ((R)-N-methyl-N-(1-methylpropyl)-1-(2-chlorophenyl)isoquinoline-3-carboxamide) as the tracer. [ 11 C]-(R)-PK11195 is a ligand for the TSPO. Although [ 11 C]-(R)-PK11195 has already been used to image activated microglia cells in, among others, stroke [5] [6] [7] [8] , multiple sclerosis [9] [10] [11] [12] , herpes encephalitis [13] , Parkinson's disease [14, 15] , and Alzheimer's disease [16] [17] [18] , it is not an ideal tracer, since it shows low brain uptake and high nonspecific binding. Pharmacokinetic modeling of the PET data is complicated and [
11 C]-(R)-PK11195 may not possess the sensitivity to visualize mild neuroinflammation, which makes it unsuitable for use in early diagnosis and detection of subtle effects of therapeutic intervention.
Therefore, a more sensitive and specific PET tracer for TSPO imaging would be of great interest. Pyrazolopyrimidines display high affinity for the TSPO and two compounds from this class have already been radiolabeled for use in PET. The pyrazolopyrimidines DPA-713 and DPA-714 have higher affinity for the TSPO in vitro (Ki=4.7 nM and Ki=7.0 nM, respectively) than PK11195 (Ki=9.3 nM) [19] [20] [21] . The TSPO antagonist DPA-713 was labeled with carbon-11 and evaluated in vivo in a healthy baboon [22] . It was concluded that [ 11 C]-DPA-713 is a specific ligand for the TSPO and that it may be useful for studying changes in the density of TSPO binding sites. In addition, [ 11 C]-DPA-713 exhibited a higher signalto-noise ratio than [ 11 C]-(R)-PK11195 in a rat model of neurodegeneration, which makes it more suitable for quantification of TSPO binding sites [23] . The TSPO agonist, DPA-714, was labeled with fluorine-18 and demonstrated good uptake in the primate brain and an eightfold higher uptake in the lesioned striatum of a quinolinic acid-lesioned rat model of activated microglia [19, 20] . This higher uptake was shown to be selective TSPO binding.
Both [19, 20, 23] . However, striatum lesion by injection of a toxic compound requires invasive manipulations to generate an inflammatory response. The aim of this study was to validate these tracers in a different rat model that does not require invasive manipulation and unnatural toxic compounds to evoke neuroinflammation, which may better mimic microglia activation in neurological disorders. Therefore, [ 11 C]-methyl iodide [24] in a solution of 1 mg (R)-N-desmethyl PK11195 and 10 mg potassium hydroxide in 300 μl dimethylsulfoxide. The reaction mixture was allowed to react for 1 min at 40°C, neutralized with 1 M HCl, and passed through a 45-μm Millex HV filter. The filtrate was purified by high-performance liquid chromatography (HPLC) using a μBondapak C18 column (7.8×300 mm) with acetonitrile/25 mM NaH 2 PO 4 (pH 3.5) (55/45) as the eluent (flow 5 ml/min). To remove the organic solvents from the product, the collected HPLC fraction (retention time 7 min) was diluted with 100 ml of water and passed through an Oasis HLB 30 mg (1 cc) cartridge. The cartridge was washed twice with 10 ml of water and subsequently eluted with 0.7 ml of ethanol and 5 ml of water. The product was sterilized by filtration over a 22 μm Millex LG filter. The product was obtained in 33±15% radiochemical yield (n=11). Quality control was performed by HPLC, using a Novapak C18 column (150×3.9 mm) with acetonitrile/25 mM NaH 2 PO 4 (pH 3.5; 60/40) as the eluent at a flow of 1 ml/min. The radiochemical purity was always 995% and the specific activity was 51±18 MBq/nmol. [22] and 2.5 μl 0.5 M NaOH in 0.5 ml of acetonitrile (Fig. 1) . After 5 min at 100°C, the reaction mixture was diluted with 0.5 ml of acetonitrile and 1 ml of water and purified by HPLC using a SymmetryPrep C18 column (7 μm, 7.8×300 mm) and acetonitrile/0.1 M NaH 2 PO 4 (1/1) as the eluent (flow 5 ml/min). The radioactive product with a retention time of 7-8 min was collected. The product was diluted with 100 ml of water and passed through an Oasis HLB 30 mg (1 cc) cartridge. The cartridge was washed twice with 10 ml of water and subsequently eluted with 0.7 ml of ethanol and 5 ml of water. The product was sterilized by filtration over a 22-μm Millex LG filter. The product is obtained in 48±15% radiochemical yield (n=10). Quality control was performed by HPLC, using a Novapak C18 column (150×3.9 mm) with acetonitrile/25 mM NaH 2 PO 4 (40/60) as the eluent at a flow of 1 ml/min. The radiochemical purity of [ 11 C]DPA-713 was always 999% and the specific activity was 41±12 MBq/nmol.
Materials and Methods
To a suspension of 42 mg 55% NaH (1.0 mmol) in 15 ml freshly distilled tetrahydrofuran (THF), 100 mg (0.44 mmol) of N,N-diethyl-2-(2-(4-hydroxyphenyl)-5,7-dimethylpyrazolo(1,5-α)pyrimidin-3-yl)acetamide (compound 1) [22] was added (Fig. 1) . After the reaction mixture was refluxed for 30 min, a solution of 300 mg (0.87 mmol) ethyleneglycol ditosylate in 20 ml THF was quickly added to the hot reaction mixture. After another 18 h of refluxing, the reaction flask was cooled on ice and the reaction was quenched by slowly adding 50 ml of water. The mixture was extracted three times with 25 ml of dichloromethane. The combined organic layers were washed with 50 ml of water, dried on anhydrous sodium sulfate, and filtered. The product was purified by flash column chromatography (silica gel), using 3% methanol in dichloromethane as the eluent. The product was obtained as a light yellow solid in 59% yield (140 mg). 
Reference material of DPA-714 (compound 4) was prepared as described for compound 3, except 2-fluoroethyl tosylate was used as the alkylating agent instead of ethyleneglycol ditosylate (Fig. 1) 18 F]KF/kryptofix complex. The reaction mixture was allowed to react for 10 min at 100°C. After cooling, the reaction mixture was diluted with water and HPLC eluent (acetonitrile/0.1 M NaH 2 PO 4 (45/55)) and passed through an Alumina N seppak to remove the majority of unreacted [ 18 F] fluoride. The product was purified by HPLC using a SymmetryPrep C18 column (7 μm, 7.8×300 mm) with acetonitrile/0.1 M NaH 2 PO 4 (45/55) as the eluent (flow 5 ml/min). To remove the organic solvents from the product, the collected HPLC fraction (retention time 11 min) was diluted with 15 ml of water and passed through an Oasis HLB 30 mg (1 cc) cartridge. The cartridge was washed with 5 ml of water and subsequently eluted with 0.7 ml of ethanol and 5 ml of water. The product was sterilized by filtration over a 22-μm Millex LG filter. The product was obtained in 17± 8% radiochemical yield. Quality control was performed by HPLC, using a Novapak C18 column (150×3.9 mm) with acetonitrile/ 25 mM NaH 2 PO 4 (35/65) as the eluent at a flow of 1 ml/min. The radiochemical purity was 999% and the specific activity was 80± 35 MBq/nmol (n=11). 
Animals
Male outbred Wistar-Unilever (SPF) rats (weight 287±38 g) were obtained from Harlan (Lelystad, The Netherlands). The rats were individually housed in Macrolon cages (38×26×24 cm) on a layer of wood shavings in a room with constant temperature (21±2°C) and fixed, 12-h light-dark regime. Food (standard laboratory chow, RMH-B, Hope Farms, The Netherlands) and water were available ad libitum. After arrival, the rats were allowed to acclimatize for at least 7 days. The rats were randomly divided into nine groups: control rats (control) scanned with either
18 F]-DPA-714 (n=5), rats infected with HSV-1 (HSE) scanned with either
18 F]-DPA-714 (n=9), and rats infected with HSV-1 and pre-treated with PK11195 (HSE pre-treated with PK11195) scanned with either
18 F]-DPA-714 (n=4). After PET scanning, the rats were killed and the ex vivo biodistribution of the tracers was determined. The study was approved by the Animal Ethics Committee of the University of Groningen, The Netherlands.
HSV-1 Inoculation
The HSV-1 strain was obtained from a clinical isolate, cultured in Vero cells and assayed for plaque forming units (PFU) per milliliter. The rats were slightly anaesthetized with 5% isoflurane (Pharmachemie BV, The Netherlands) and inoculated with HSV-1 by the application of 100 μl of phosphate-buffered saline (PBS) with 1×10 7 PFU of virus on the nostrils (50 μl per nostril) with a micropipette. Control rats were treated similarly by the application of 100 μl PBS without virus. Clinical symptoms in all rats were scored daily after the inoculation by the same observer.
Immunohistochemistry
Immunohistochemical staining was performed in control and HSV-1-infected rats on day 7 after inoculation. The rats were euthanized and the brains were removed and frozen at −80°C. Coronal brain sections of 10 μm were cut at −18°C using a cryostat (Leica Microsystems, Germany). Sections were collected on slides, vacuum-dried, fixated for 20 min in paraformaldehyde (4% in 100 nM PBS), and washed three times for 5 min in 100 nM PBS. To block non-specific binding, sections were incubated with 5% normal goat serum in PBS containing 3% triton and washed for 5 min in 100 nM PBS. Sections were incubated overnight at 4°C with the primary antibody (Anti Iba1 Rabbit (1:750), Wako Chemicals, USA). After incubation, sections were washed three times for 5 min in 100 nM PBS and incubated for 1 h with the secondary antibody (FITC-conjugated Goat Anti Rabbit IgG (1:250), Jackson ImmunoResearch Laboratories Inc., USA) in 1% normal goat serum in PBS containing 3% triton. As a negative control, sections were only incubated with the secondary antibody. Subsequently, sections were washed three times for 5 min in PBS and mounted with Mowiol mounting medium. The fluorescence was examined by using a microscope (Zeiss Axioskop 2, Carl Zeiss Microimaging Inc., Germany) in combination with the Leica Application Suite (Version 2.3.3 R1, Leica, Germany).
PET Studies
PET scans were performed when robust clinical signs of infection appeared, which was either on day 6 or on day 7 after the inoculation with HSV-1. The rats were anesthesized by an intraperitoneal injection of medetomidine (Domitor, Pfizer, The Netherlands, 0.2 mg/kg) and ketamine (Ketanest, Pfizer, The Netherlands, 25 mg/kg), after which the rats were positioned in the small animal PET camera (Focus 220, Siemens Medical Solutions USA, Inc.) in transaxial position with their heads in the field of view. A transmission scan of 515 s with a Co-57 point source was obtained for the correction of attenuation by tissue. After the transmission scan was completed, the PET tracer [ The list-mode data of the emission scans was separated into 21 frames (8×30, 3×60, 2×120, 2×180, 3×300, and 3×600 s) for [ 
PET Image Analysis
PET image analysis was performed using the Clinical Applications Packaging Program (CAPP5). Regions of interest were drawn around the bulbus olfactorius, frontal cortex, striatum, parietal/ temporal/occipital cortex, brainstem, and cerebellum in a template PET scan that was co-registered with the PET scan of interest by image fusion. The time-activity curves per region of interest were determined in becquerel per cubic centimeter units and converted into standardized uptake values (SUV), defined as: [tissue activity concentration (MBq/g)]/[(injected dose (MBq)/body weight (g)]. It was assumed that 1 cm 3 of brain tissue equals 1 g. To correct for the activity in plasma, each point on the time-activity curve (SUV) was divided by the ex vivo plasma uptake (SUV) at t=60 min for [ 
Ex Vivo Biodistribution
After the PET scan, the rats were killed by extirpation of the heart while under deep anesthesia. The brain was dissected into several brain areas, peripheral organs were excised, and blood was centrifuged to collect a plasma sample. The brain areas, peripheral organs, and plasma were weighed and analyzed for the amount of radioactivity by using a gammacounter (LKB Wallac, Turku, Finland). Tracer uptake is expressed as the SUV.
To correct for activity of the tracers in plasma, the tissue/plasma ratio was calculated by dividing the uptake (SUV) in the different brain areas by the plasma uptake (SUV), for all rats individually. Subsequently, the TSPO-specific uptake was calculated for control and HSE rats. The specific uptake was calculated by subtracting the average tissue/plasma ratio of the HSE rats pre-treated with PK11195 from the tissue/plasma ratio of control and HSE rats, for each rat individually.
Statistical Analysis
All data are expressed as mean ± standard deviation. Statistical analysis was performed using SPSS for Windows, version 14.0.2. Statistical analysis on differences between the uptake of [
11 C]-(R)-PK11195, [ 11 C]-DPA-713, and [ 18 F]-DPA-714, which were obtained from the PET scan, was performed by one-way ANOVA. Per brain area, a Bonferonni post hoc test was used to determine if there were differences in uptake between the PET tracers. For the ex vivo biodistribution, statistical analysis on differences in uptake between control rats, HSE rats, and HSE rats pre-treated with PK11195 was performed by one-way ANOVA, using a Bonferonni post hoc test to compare the three conditions per brain area. Statistical analysis on differences between non-specific and specific uptake of [ [25] were assessed with Pearson's product moment correlation coefficient (r). Significance was reached when the p value was G0.05.
Results

Clinical Symptoms
Clinical symptoms were scored daily up to 7 days postinoculation and categorized into the following clinical scores: (0), no symptoms; (1), ruffled fur and irritated mouth, nose, and eyes; (2), behavioral signs, like stress and lethargy, and hunched posture; (3), posterior paralysis and impairment of motor function; and (4), severe paralysis, labored breathing or death. The first clinical symptoms in the HSE rats were seen on day 4 or 5 after inoculation with HSV-1, after which the severity of the symptoms increased. 
Immunohistochemistry
At day 7 after inoculation with HSV-1, intense microglial activation was observed in the bulbus olfactorius, cerebellum, and brainstem (Fig. 2) . In addition, mild microglial activation was also seen in the frontal cortex and hippocampus of HSV-1-infected rats. The activated microglia cells could be recognized by the rounded shape with short processes, showing that the microglia cells had converted to the macrophage-like state. Microglial activation in the brainstem was observed throughout the whole brainstem and could not be attributed to a specific area. In control rats, only ramified, resting microglia cells were observed in all brain areas.
Small Animal PET Imaging
The standardized uptake values obtained from the last 10 min of the PET scans are displayed in Table 1 . The uptake of [ 11 C]-(R)-PK11195 in the last 10 min of the scan was significantly higher in the bulbus olfactorius, frontal cortex, parietal/temporal/occipital cortex, cerebellum, and brainstem in HSE rats when compared to control rats. The uptake was consistent with the immunohistochemistry data. The [
11 C]-(R)-PK11195 uptake in the rats pre-treated with PK11195 was significantly decreased in the bulbus olfactorius, cerebellum, and brainstem. For [ 11 C]-DPA-713, a significant increase in tracer uptake was found in the brainstem and a nonsignificant increase in the bulbus olfactorius of HSE rats, as compared to control rats. Also, [ The time-activity curves of the brainstem are displayed in Fig. 3 , to show the kinetics of the tracer over time. These time-activity curves were normalized for activity in plasma because tracer uptake in the brain is dependent on the tracer delivery from plasma. A change in plasma activity concentration due to, for example, pre-treatment with PK11195 can thus influence brain uptake. For plasma activity normalization, the uptake (SUV) on each individual time point was divided by the activity in plasma (SUV) as determined ex vivo on t=60 for [ 11 C]-(R)-PK11195 in the brainstem of HSE rats was significantly higher than that of control rats (pG0.005) and rats pre-treated with PK11195 (pG0.005). For [
11 C]-DPA-713, the time-activity curve in HSE rats was significantly higher than in the control rats (pG0.05) and in rats pre-treated with PK11195 (pG0.005). In addition, the uptake of [ 11 C]-DPA-713 over time was significantly reduced by pre-treatment with PK11195, even when compared to control rats (pG0.05). No differences in timeactivity curves of control, HSE, and pre-treated rats were found for [ 18 F]-DPA-714 in the brainstem, although pretreatment with PK11195 non-significantly reduced the uptake in the brainstem.
Ex Vivo Biodistribution: SUV
An ex vivo biodistribution study of the three PET tracers was performed to confirm the results of the PET studies. In addition, biodistribution allows investigation of uptake in smaller brain areas than is possible with small animal PET imaging. The ex vivo biodistribution, expressed as mean SUV ± SD, was consistent with the results obtained from the PET images. Uptake of [
11 C]-(R)-PK11195 ( The ex vivo biodistribution of [ 11 C]-DPA-713 is shown in Table 3 . As was found for [ 11 C]-(R)-PK11195, the bulbus olfactorius in HSE rats showed an increase in [
11 C]-DPA- Table 2 . Ex vivo biodistribution of [ 11 C]-(R)-PK11195, expressed as standardized uptake values (SUV; mean ± SD), 60 min after tracer injection in control rats (control; n=5), rats infected with HSV-1 (HSE; n=9), and rats infected with HSV-1 pre-treated with 5 mg/kg PK11195 5 min before tracer injection (HSE + PK11195; n=4) 
Ex Vivo Biodistribution: Specific Binding
The ex vivo biodistribution showed an increased binding in HSE rats as compared to controls and a decreased binding after pre-treatment with PK11195, for all three PET tracers. However, plasma levels of the tracer were also found to be different between the three PET tracers and between treatment groups. Since tracer accumulation in the brain is dependent on tracer delivery (and thus tracer concentration) from plasma, the brain uptake was corrected for plasma radioactivity for each rat individually to calculate the tissue/ plasma ratios.
Non-specific binding and specific binding of Table 5 . Non-specific binding was defined as the tissue/ plasma ratio of rats pre-treated with PK11195. Specific binding was calculated in control and HSE rats, by subtracting the average tissue/plasma ratio of the HSE rats pre-treated with PK11195 from the tissue/plasma ratio of control and HSE rats, for each rat individually. The rationale behind the definition of specific uptake is that the uptake in rats pre-treated with PK11195 represents non-specific binding only, whereas the uptake in control and HSE rats is due to both specific and non-specific binding. Non-specific binding was found to be statistically significantly lower in almost all brain areas for both [ 11 C]-DPA-713 uptake might be most sensitive to changes in TSPO expression. Although these results seem to depend on the bulbus olfactorius, which has the highest uptake, the correlation remained good after removal of this data point from the regression analysis. In addition, the slope of the linear regression remained highest for [ 11 C]-DPA-713.
Discussion
In the present study, the new TSPO ligands [ 11 C]-DPA-713 and [
18 F]-DPA-714 were evaluated in a rat model of herpes The TSPO that is only modestly expressed in the healthy brain is upregulated in microglia cells when they become activated in response to inflammatory stimuli and brain damage. Microglia cells are increasingly associated with neurological diseases, such as Parkinson's disease [15] and multiple sclerosis [9] , and are therefore an important target for early diagnosis and detection of the subtle effects of therapeutic intervention. At present, the most widely used PET tracer to visualize activated microglia is the TSPO ligand [
11 C]-(R)-PK11195, but this radiotracer may not provide the required sensitivity. The high lipophilicity and high non-specific binding of [ 11 C]-(R)-PK11195 result in a low signal-to-noise ratio, which makes detecting mild 
